Table 1 Baseline characteristics of the patient cohort (n = 379) including metastasis proportion
Variable | Number of patientsa | % total | Number with metastasis | % metastasis |
|---|---|---|---|---|
Sex | ||||
 Female | 139 | 36.7% | 29 | 20.9% |
 Male | 240 | 63.3% | 52 | 21.7% |
Age | ||||
 ≤60 | 157 | 41.4% | 41 | 26.1% |
 60–70 | 154 | 40.6% | 29 | 18.8% |
 > 70 | 68 | 17.9% | 11 | 16.2% |
Familial risk | ||||
 Low | 196 | 51.7% | 34 | 17.3% |
 Intermediate/High | 183 | 48.3% | 47 | 25.7% |
5-FU based treatment | ||||
 5-FU treated | 214 | 56.5% | 59 | 27.6% |
 Other/No chemo | 159 | 42.0% | 17 | 10.7% |
 Unknown | 6 | 1.6% | 5 | 83.3% |
Stage | ||||
 I | 81 | 21.4% | 8 | 9.9% |
 II | 158 | 41.7% | 30 | 19.0% |
 III | 140 | 36.9% | 43 | 30.7% |
Location | ||||
 Colon | 233 | 61.5% | 41 | 17.6% |
 Rectum | 146 | 38.5% | 40 | 27.4% |
Histology | ||||
 Non-mucinous | 343 | 90.5% | 75 | 21.9% |
 Mucinous | 36 | 9.5% | 6 | 16.7% |
Vascular invasion | ||||
 Absence | 242 | 63.9% | 45 | 18.6% |
 Presence | 111 | 29.3% | 30 | 27.0% |
 Unknown | 26 | 6.9% | 6 | 23.1% |
Lymphatic invasion | ||||
 Absence | 237 | 62.5% | 44 | 18.6% |
 Presence | 116 | 30.6% | 31 | 26.7% |
 Unknown | 26 | 6.9% | 6 | 23.1% |
BRAF V600E mutation | ||||
 Absence | 333 | 87.9% | 72 | 21.6% |
 Presence | 19 | 5.0% | 8 | 42.1% |
 Unknown | 27 | 7.1% | 1 | 3.7% |